Novel 2,4,6-Trisubstituted 1,3,5-Triazines as CX3CR1 Modulators for the Treatment of Cardiovascular Disorders

This patent application describes a novel series of 2,4,6-trisubstituted 1,3,5-triazines compounds represented by Formula I. These compounds hold promise for the treatment of cardiovascular disorders, including nonischemic dilated cardiomyopathy and heart failure.

Institutions

Emory University (US)

Publication Details

Journal: ACS Medicinal Chemistry Letters
Published: 2025-12-12
DOI: https://doi.org/10.1021/acsmedchemlett.5c00691
Primary Topic: Synthesis and Characterization of Heterocyclic Compounds
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Novel 2,4,6-Trisubstituted 1,3,5-Triazines as CX3CR1 Modulators for the Treatment of Cardiovascular Disorders

Dec 12, 2025

ACS Medicinal Chemistry Letters

Synthesis and Characterization of Heterocyclic Compounds

article

Novel 2,4,6-Trisubstituted 1,3,5-Triazines as CX3CR1 Modulators for the Treatment of Cardiovascular Disorders

December 12, 2025article en

Abstract

ACS Medicinal Chemistry LettersVol. 17(1)

Emory University (US)

Good health and well-being

Openalex Percentile: Top 35%

Synthesis and Characterization of Heterocyclic Compounds

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Novel 2,4,6-Trisubstituted 1,3,5-Triazines as CX3CR1 Modulators for the Treatment of Cardiovascular Disorders · ACS Medicinal Chemistry Letters (2025) | TGRS Research Map | TGRS